Validation of combined Monte Carlo and photokinetic simulations for the outcome correlation analysis of benzoporphyrin derivative-mediated photodynamic therapy on mice
Open Access
- 14 March 2019
- journal article
- research article
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 24 (03) , 035006-9
Abstract
Photodynamic therapy (PDT) has been approved by the U.S. Food and Drug Administration for the treatment of esophageal cancer, non-small cell lung cancer, Barrett’s esophagus, and age-related macular degeneration.1 – 6 Two types of PDT killing mechanisms are known to exist when utilizing light-activated photosensitizers (PSs) to generate reactive oxygen species that kill cancer cells. Type I PDT generates superoxide anion () and other secondary oxygen species, such as hydroxyl radicals () or hydrogen peroxide () for treatment.7 Many commonly used PSs are type II. Type II PDT is a complex process7 involving the interactions of the local photosensitizer concentration [PS], the local light fluence rate (intensity or ), and the local oxygen concentration [] in order to produce singlet oxygen (). Furthermore, the local light fluence rate depends on light transmission through intervening tissue having local absorption coefficient, , and local reduced scattering coefficient, . The complexity of the type II PDT process has made monitoring of treatments difficult and unreliable. Many clinical studies have not resulted in optimal treatment due to the lack of reliable dosimetry for singlet oxygen.6
Keywords
Funding Information
- National Institutes of Health (R44CA183236)
This publication has 49 references indexed in Scilit:
- Insights into Photodynamic Therapy Dosimetry: Simultaneous Singlet Oxygen Luminescence and Photosensitizer Photobleaching MeasurementsBiophysical Journal, 2012
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modelingJournal of Biophotonics, 2010
- System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancerJournal of Biomedical Optics, 2010
- Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapyPhotochemical & Photobiological Sciences, 2009
- Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancerPhysics in Medicine & Biology, 2009
- Motexafin Lutetium-Photodynamic Therapy of Prostate Cancer: Short- and Long-Term Effects on Prostate-Specific AntigenClinical Cancer Research, 2008
- Optimization of light source parameters in the photodynamic therapy of heterogeneous prostatePhysics in Medicine & Biology, 2008
- The role of photodynamic therapy (PDT) physicsMedical Physics, 2008
- Determination ofin vivolight fluence distribution in a heterogeneous prostate during photodynamic therapyPhysics in Medicine & Biology, 2008